Novo is a leading global healthcare company, founded in 1923 and headquartered in Denmark.
We believe lasting health starts now.
We pioneer scientific breakthroughs, expand access to our medicines, and work to in strategic partnerships to create meaningful change for millions of people living with chronic diseases.
- Legal name: Novo Nordisk A/S
- Founded: 1923
- President and CEO: Maziar Mike Doustdar
Our heritage
Meet Mike
Executive management
- Therapy areas: Diabetes, Obesity, Rare Disease, Cardiovascular & Emerging Therapy Areas
- Globally serving more than 46.5 million people living with serious chronic diseases
Learn more about our therapy areas
- Number of employees: 67,000
- Number of employees in DK: 33.700
- Number of employees in US: 11.200
- Affiliates in 80 countries
- Strategic production sites in Belgium, Brazil, China, Denmark, France, Italy and the US
- R&D facilities in China, Denmark, UK, US and India
- Investing more than 17.7 bn DKK in R&D in Q2 2026
Our R&D pipeline
Research & technology centres
- Net sales in Q2 2026: 78.4 bn DKK
- Operating profit in Q2 2026: 27 bn DKK
- Net profit in Q2 2026: 20.9 bn DKK
Explore our results in 2025
Annual Report 2024
- Corporate income tax in Denmark in Q2 2026: 7 bn DKK